See more : Gi Group Poland S.A. (GIG.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Adagene Inc. (ADAG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adagene Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Pharmena S.A. (PHR.WA) Income Statement Analysis – Financial Results
- Ningbo Zhongbai Co., Ltd. (600857.SS) Income Statement Analysis – Financial Results
- Presidential Realty Corporation (PDNLB) Income Statement Analysis – Financial Results
- Medios AG (MEDOF) Income Statement Analysis – Financial Results
- Atal Realtech Limited (ATALREAL.NS) Income Statement Analysis – Financial Results
Adagene Inc. (ADAG)
About Adagene Inc.
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 18.11M | 9.29M | 10.18M | 480.00K | 480.00K | 1.51M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 18.11M | 9.29M | 10.18M | 480.00K | 480.00K | 1.51M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 36.64M | 81.34M | 68.10M | 16.21M | 16.21M | 16.08M |
| General & Administrative | 8.67M | 11.87M | 14.44M | 3.44M | 3.44M | 2.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.67M | 11.87M | 14.44M | 3.44M | 3.44M | 2.77M |
| Other Expenses | -3.48M | 2.17M | 1.78M | 723.48K | 723.48K | 901.71K |
| Operating Expenses | 41.83M | 93.21M | 82.54M | 19.65M | 19.65M | 18.85M |
| Cost & Expenses | 41.83M | 93.21M | 82.54M | 19.65M | 19.65M | 18.85M |
| Interest Income | 4.28M | 377.50K | 76.17K | 922.68K | 922.68K | 710.71K |
| Interest Expense | 1.11M | 693.32K | 363.76K | 138.10K | 138.10K | 91.09K |
| Depreciation & Amortization | 1.21M | 1.43M | 1.13M | 858.41K | 816.69K | 909.00K |
| EBITDA | -14.95M | -77.39M | -69.99M | -41.34M | -15.48M | -14.27M |
| EBITDA Ratio | -82.55% | -875.68% | -692.95% | -3,650.73% | -3,480.59% | -980.24% |
| Operating Income | -23.72M | -83.92M | -72.36M | -19.17M | -19.17M | -17.33M |
| Operating Income Ratio | -130.97% | -903.08% | -711.18% | -3,993.68% | -3,993.68% | -1,147.09% |
| Total Other Income/Expenses | 6.46M | 4.41M | 887.77K | 754.38K | 2.74M | 2.07M |
| Income Before Tax | -17.25M | -79.51M | -71.48M | -16.43M | -16.43M | -15.27M |
| Income Before Tax Ratio | -95.27% | -855.65% | -702.45% | -3,423.40% | -3,423.40% | -1,010.22% |
| Income Tax Expense | 1.69M | 459.06K | 1.70M | 3.16K | 861.57K | -547.00K |
| Net Income | -18.95M | -79.97M | -73.18M | -16.44M | -17.29M | -14.72M |
| Net Income Ratio | -104.61% | -860.59% | -719.18% | -3,424.06% | -3,602.89% | -974.03% |
| EPS | -0.44 | -1.85 | -1.83 | -0.47 | -0.39 | -0.43 |
| EPS Diluted | -0.43 | -1.85 | -1.83 | -0.47 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 43.31M | 43.31M | 40.03M | 35.08M | 44.17M | 34.41M |
| Weighted Avg Shares Out (Dil) | 43.79M | 43.31M | 40.03M | 35.08M | 44.17M | 34.41M |
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
Adagene to Participate in Investor Conferences in May and June
Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
Investors Hoping for News at Cancer Meeting That Will Boost Share Prices
Sanofi to pay up to $2.5 billion in deal with Adagene
Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study
Adagene Shares Jump After FDA Signs Off ADG116/Keytruda Combo Therapy Trial In Solid Tumors
Source: https://incomestatements.info
Category: Stock Reports